List view / Grid view
More effective drugs could be developed due to a new technique that has allowed scientists to decipher how millions of individual cells are communicating with each other on miniature tumours grown in a lab.
Researchers have developed a way to produce proteins from lettuce which can effectively combat pulmonary arterial hypertension in animals.
A group of researchers, led by Professor Zucai Suo, have revealed the mode of action of two HIV drugs and identified how resistance can develop, which they say could lead to improved drug design in the future.
The experimental remdesivir drug has shown efficacy in combatting the MERS virus in rhesus macaques, according to a new US study.
Researchers have engineered a chip which allows 3D modelling of the blood-brain-barrier and has provided insight into how astrocytes facilitate transport of molecules.
An innovative new vaccine technique, which sensitises the immune system to the genetic signature of APOBEC mutations (often found in cancers), increases the efficacy of immunotherapies.
Researchers have created a CAR T-cell therapy which targets the CD229 molecule expressed on all multiple myeloma cells and killed human tumour cells in mice.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
Researchers have provided new insight into the role of cyclic AMP (cAMP) in regulating the immune response which may lead to new ways of treating diseases.
To address the receptor dysfunction associated with several neurological diseases, scientists have provided novel insights into a protein-protein interaction that could lead to more effective treatments.
Research into alternative stem cell sources has identified urine derived renal progenitor cells (UdRPCs) as a possible option for use in regenerative kidney therapies in the future.
A new study has shown in three dimensions how drugs bind to HIV, which could be used to improve the design of drugs or develop novel therapies.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
Scientists have produced hundreds of organoids which they say could be produced on a large-scale as a low-cost tissue model to help research and test new medulloblastoma therapies.
Scientists have discovered three major pro-inflammatory mediators that drive capillary loss and identified drug combinations to prevent the degeneration of these tiny blood vessels.
